India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...

The company's Consumer Wellness business registered revenues of Rs. 448.8 crore, up 13 % y-o-y with 4.8% volume growth.

Zydus Wellness Ltd (BOM:531335) reports robust sales growth and market leadership amid inflationary pressures and urban demand challenges.

Zydus Wellness’ revenue from operations stood at ₹450.8 crore in the December 2024 quarter, rising 12.7% on a YoY basis.

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...

The board approved the demerger of the consumer products division of Cadila Healthcare into Carnation, which is a subsidiary of Cadila Healthcare and the merger of Zydus Hospital and Medical ...

CEO of Zydus Wellness. According to Arora, rural consumers aspire to the same products as urban consumers, but with an emphasis on more accessible, lower-unit packs. The push towards smaller ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...